Related Experiment Video
Updated: May 15, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting
Clifton Ming Tay1, Chee Wee Ong, Victor Kwan Min Lee
1Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Abstract:
Gain-of-function mutations involving c-kit protein, a cell-surface transmembrane receptor for stem cell factor, have been identified as a key oncogenic driver in a variety of solid tumours. Coupled with the development of tyrosine kinase inhibitors such as imatinib, c-kit has emerged as a viable drug target in what seems to be a validated therapeutic concept. This review will focus on gastrointestinal stromal tumours and melanomas, two types of solid tumours most closely associated with KIT gene mutations. The biology of KIT mutations in both conditions, as well as the value of KIT mutation testing in predicting disease and treatment outcomes are discussed. Since initial response to imatinib is largely influenced by mutation status, genotyping these tumours serves to facilitate personalised oncology. We also summarise our experience with diagnostic reporting of KIT mutation analysis over a period of 3 years, and briefly survey future developments in treatment, which indeed look very promising.
Insights
Gain-of-function mutations in the KIT gene drive certain cancers like GIST and melanoma. KIT mutation testing guides personalized treatment with targeted therapies such as imatinib.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gain-of-function mutations in the c-kit protein, a receptor tyrosine kinase, are key drivers in various solid tumors.
- The c-kit pathway is a validated therapeutic target, particularly with the advent of tyrosine kinase inhibitors like imatinib.
Purpose of the Study:
- To review the role of KIT mutations in gastrointestinal stromal tumors (GIST) and melanomas.
- To discuss the diagnostic value of KIT mutation testing for predicting disease and treatment outcomes.
- To summarize diagnostic reporting experiences and survey future treatment developments.
Main Methods:
- Literature review focusing on KIT biology, mutations, and therapeutic implications in GIST and melanoma.
- Analysis of diagnostic reporting data for KIT mutation analysis over a 3-year period.
Main Results:
- KIT mutations are central to the oncogenesis of GIST and melanoma.
- KIT mutation status significantly influences initial response to imatinib therapy.
- Genotyping facilitates personalized oncology by guiding treatment selection.
Conclusions:
- KIT mutation analysis is crucial for personalized treatment strategies in KIT-driven cancers.
- Targeted therapies and ongoing research show promising future developments for these malignancies.
Related Concept Videos
02:18Cancer
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:17Karyotyping